Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Reviews Options For European Business, Adopts New Manufacturing Processes

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline will implement a new £1.5 billion restructuring program to improve commercial efficiencies in Europe and adopt new manufacturing processes, following sales and profits shortfalls in 2012.


Related Content

U.S. Biotechs Strike Out Across Europe
GSK Bundles Legacy Drugs Into Separate Portfolio In Housekeeping Move
In Brief
Emerging Markets Earnings Roundup: Sanofi And GSK (Part 6)
Sanofi Navigates Patent Cliff, Expects Growth To Return In Second Half 2013
GSK To Downplay Europe Because of Poor Innovation Support, Focuses On U.S. and Japan Instead
Pfizer/GSK Unveiling HIV Joint Venture As ViiV Healthcare


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts